Literature DB >> 11951471

Management of traumatic optic neuropathy.

T C Spoor1, J G McHenry.   

Abstract

Visual loss caused by trauma to the optic nerve is a well-recognized sequela to cranio-maxillofacial trauma. The authors reviewed their experience with 90 patients with pure traumatic optic neuropathy and optic nerve trauma with concomitant maxillofacial injuries. All patients were treated with intravenous steroids. Those not improving underwent extracranial optic canal decompression. Patients with initial visual acuity of 20/100 or better all responded favorably with improvement in visual acuity or visual field to a course of intravenous megadose corticosteroids. Patients with initial vision of 20/200 or worse who failed to respond to corticosteroids may have improved visual function after undergoing extracranial optic canal decompression. Preoperative and postoperative computed tomography scans on 6 patients enhanced with intrathecal iopamidol indicate the site of optic nerve compression to be at the optic canal. This article discusses the diagnosis and the medical and surgical treatment of pure and complex optic nerve injuries.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 11951471

Source DB:  PubMed          Journal:  J Craniomaxillofac Trauma        ISSN: 1074-3219


  4 in total

Review 1.  Post-traumatic visual loss.

Authors:  Edward J Atkins; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

2.  Orbital Roof Fractures: A Clinically Based Classification and Treatment Algorithm.

Authors:  Felicity Victoria Connon; S J B Austin; A L Nastri
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-12-17

3.  Diagnosis and management of three optic neuropathies: a national survey.

Authors:  Haeng-Jin Lee; Hyuna Kim; Ju-Yeun Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-05-06       Impact factor: 3.117

Review 4.  Controversies in neuro-ophthalmology: steroid therapy for traumatic optic neuropathy.

Authors:  Rohit Saxena; Digvijay Singh; Vimla Menon
Journal:  Indian J Ophthalmol       Date:  2014-10       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.